Publications
Detailed Information
High serum allograft inflammatory factor 1 is associated with poor response to TNFα inhibitors in ankylosing spondylitis patients
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 이은영 | - |
dc.contributor.author | 이은영 | - |
dc.date.accessioned | 2018-05-29T04:54:28Z | - |
dc.date.available | 2018-05-29T04:54:28Z | - |
dc.date.issued | 2018-02 | - |
dc.identifier.other | 000000151165 | - |
dc.identifier.uri | https://hdl.handle.net/10371/142331 | - |
dc.description | 학위논문 (석사)-- 서울대학교 대학원 : 의과대학 의학과, 2018. 2. 이은영. | - |
dc.description.abstract | Background: Anti-TNFα therapy has been proven to be highly efficacious in ankylosing spondylitis (AS). Considering its high costs and potential risk for adverse events, early detection of non-responders to anti-TNFα agents is critical.
Objectives: To identify serum markers predicting clinical response to TNFα blockers in AS Methods: Baseline gene expression differences were screened by pathway focused gene assays of peripheral blood RNA from 6 AS patients (3 responders and 3 non-responders) before initiating anti-TNFα treatment, and selected results were confirmed by qRT-PCR in 18 patients (11 responders and 7 non-responders). Concentration of corresponding serum protein was measured by ELISA and compared in 69 responders and 48 non-responders. No response to TNFα blocker was defined as less than 50% improvement in Bath ankylosing spondylitis disease activity score (BASDAI) at week 14 from baseline. Results: Nine candidate genes were selected from gene assays and validated by qRT-PCR. Among these genes, the expression of allograft inflammatory factor 1 (AIF1) was 3.52 fold higher in non-responders than responders (p=0.032). The serum AIF1 level at baseline was significantly higher in BASDAI 50 non-responders | - |
dc.description.abstract | median 32.8 [IQR 20.6 | - |
dc.description.abstract | 67.3] pg/ml in responders and 54.2 [28.9 | - |
dc.description.abstract | 91.0] pg/ml in nonresponders
(p=0.033). AIF1 level of 63.5 pg/ml or more was associated with higher risk for BASDAI > 5.0 at week 14 after anti-TNFα treatment (adjusted OR 6.953, p=0.002). Conclusion: Baseline serum AIF1 level was higher in TNFα blocker non-responders. After adjusting age and initial BASDAI, high concentration of baseline AIF1 was associated with high disease activity after TNFα blocker treatment. These results suggest that AIF1 may be a novel serum marker for predicting non-responders to anti-TNFα therapy in AS. | - |
dc.description.tableofcontents | I. Introduction 1
II. Subjects and Methods 4 III. Results 11 IV. Discussion 30 V. References 35 | - |
dc.format | application/pdf | - |
dc.format.extent | 1132863 bytes | - |
dc.format.medium | application/pdf | - |
dc.language.iso | en | - |
dc.publisher | 서울대학교 대학원 | - |
dc.subject | Ankylosing spondylitis | - |
dc.subject | anti-TNF | - |
dc.subject | allograft inflammatory factor 1 | - |
dc.subject | AIF1 | - |
dc.subject | BASDAI | - |
dc.subject | serum marker | - |
dc.subject.ddc | 610 | - |
dc.title | High serum allograft inflammatory factor 1 is associated with poor response to TNFα inhibitors in ankylosing spondylitis patients | - |
dc.type | Thesis | - |
dc.description.degree | Master | - |
dc.contributor.affiliation | 의과대학 의학과 | - |
dc.date.awarded | 2018-02 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.